U.S. Markets open in 1 hr 43 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
250.80-2.17 (-0.86%)
At close: 4:00PM EDT

253.19 2.39 (0.95%)
Pre-Market: 5:15AM EDT

People also watch
CELGREGNGILDAMGNALXN
Interactive chart
Previous Close252.97
Open252.59
Bid248.10 x 200
Ask254.20 x 200
Day's Range250.51 - 253.61
52 Week Range223.02 - 333.65
Volume765,685
Avg. Volume1,557,003
Market Cap53.57B
Beta0.51
PE Ratio (TTM)15.71
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 days ago

    UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation

    A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc's Tysabri and who had received a single dose of Ocrevus in April. Roche is trying to determine the source of the illness but MS drugs that suppress the immune system can increase the risk of serious infections.

  • Which Biotechs Benefit Most Under Trump's Tax Reform Vision?
    Investor's Business Daily3 days ago

    Which Biotechs Benefit Most Under Trump's Tax Reform Vision?

    Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.

  • Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
    Zacks4 days ago

    Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

    Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.